A Single Dose, Two – stage, Fasting State, Bioequivalence Study of Rifaximin 200 mg, film-coated tablets (Antibiotice S.A.) vs. Normix® 200 mg, film-coated tablets (Alfasigma S.p.A)
Phase 1
- Conditions
- healthy subjectsTherapeutic area: Diseases [C] - Digestive System Diseases [C06]Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Registration Number
- CTIS2024-510671-38-00
- Lead Sponsor
- Antibiotice S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method